LinkedIn·Wednesday, 19 August 2026·6d ago
We know RBQM improves oversight. But what's it actually worth? In a new Q&A with ACRP, Sylviane de Viron (CluePoints) and Abigail Dirks, MS…
CluePoints
15,590 followers
We know RBQM improves oversight. But what's it actually worth?
In a new Q&A with ACRP, Sylviane de Viron (CluePoints) and Abigail Dirks, MS (Tufts CSDD) break down the peer-reviewed research that puts real numbers to the financial case for risk-based quality management.
The headline findings:
→ Up to 23x ROI at the clinical trial level
→ 8 to 19% reductions in clinical phase durations
→ Up to 18% lower monitoring costs under a 10% SDV scenario
The biggest driver of value? Time saved. As the authors point out, protecting development timelines is one of the strongest strategic levers sponsors have, and RBQM delivers on it.
Read the full Q&A here: https://lnkd.in/eRJUj4WP
#RBQM #ClinicalTrials #ClinicalResearch #DrugDevelopment
Making the Financial Case for Risk-Based Quality Management in Clinical Research - ACRP
https://hubs.ly/Q04twV4M0
♥ 20↻ 2
View on LinkedIn Cross-referenced
Related on the wire
The RBQMLive 2026 agenda is live. Six years in, and the conversation has moved from "should we do RBQM" to "how do we prove it works." That…
83% of sites improved trial quality when central statistical monitoring was applied. Only 56% improved without it. In the Summer issue of…
We’re bringing the launch to the rooftop. 🎉 Join CluePoints at Urban Oak Rooftop Bar on Tuesday, September 15, as we celebrate the launch…
Are you ready to make the business case for RBQM? Join us for our upcoming webinar, where experts from CluePoints and the Tufts Center for…
The CRA role isn't shrinking. It's being elevated. For years, the job meant high-volume source data verification and box-checking against…
Real-world data is only as valuable as it is trustworthy. In her latest piece for PharmaLive, CluePoints Senior Strategic Consultant Sophie…